Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | PIM1 | P11309 | 9/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794569 | 1.00 | RAB9A (0.57) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL2880695 | 1.00 | RAB9A (0.57) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL16762276 | 0.88 | PIM1 (0.64) | RAB9APIK3CAPIK3CGPIM1CISD1 | |
| SCHEMBL16762271 | 0.88 | PIM1 (0.64) | RAB9APIK3CAPIK3CGPIM1CISD1 | |
| SCHEMBL16762261 | 0.88 | MEN1 (0.55) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL16762274 | 0.88 | PIM1 (0.64) | RAB9APIK3CAPIK3CGPIM1CISD1 | |
| SCHEMBL16762263 | 0.88 | MEN1 (0.55) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL27985070 | 0.84 | CLK1 (0.46) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL2882186 | 0.78 | IGF1R (0.59) | RAB9APIK3CAPIK3CGNPC1IGF1R | |
| SCHEMBL2882182 | 0.78 | IGF1R (0.59) | RAB9APIK3CAPIK3CGNPC1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | RAB9A 1515/4885PIK3CA 619/4885PIK3CG 1265/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | RAB9A 1524/4885PIK3CA 17/4885PIK3CG 52/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | RAB9A 1737/4885PIK3CA 130/4885PIK3CG 110/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | RAB9A 1949/4885PIK3CA 29/4885PIK3CG 52/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | RAB9A 1504/4885PIK3CA 559/4885PIK3CG 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.